LIVE: FDA Announces Steps to Implement Real-Time Clinical Trials

Live News Network
1.4K followers
3 Video Views·Apr 28, 2026
The Food and Drug Administration announces major steps to advance the implementation of real-time clinical trials at 1:30 p.m. ET on April 28.
Good afternoon everyone and thank you for joining us today. We appreciate you being here for today's
very exciting announcement. I want to thank our speakers for their leadership today and the press
in advance for covering this important work. It is now my pleasure to introduce FDA Commissioner
Dr. Marty McKay. Great, thank you Emily. Thank you Emily. What an exciting day this is.
For the last 50 years, the medical profession has sadly grown to accept a 10 to 12 year time frame
for new drugs to come to market. And as a result, patients are getting drugs in a delayed fashion
when they could be getting them sooner. Today is a milestone day for us to challenge that
deeply held assumption that it must take 10 to 12 years. We have to ask some big questions. Can
we do better? Can we use new technology? Can we make our communications with sponsors more
efficient? Very few people know that 45 percent of the drug development time is dead time. That is
45 percent of the time between the initiation of the phase one clinical trial and the FDA application
at the end. There is no ongoing clinical trial. Investigators and staff are doing paperwork
and other tasks, many of which are tedious. In one case, the FDA received an application
that was 66 million pages. It's a joke. I mean it's not a joke that it was 66 million pages.
It's a joke that there was an application that was 66 million pages. We can do better.
We can introduce a radical modern concept called the page limit. Companies are spending years
on the tedious tasks. They don't like doing it and we don't need them to do it sometimes.
After a trial is complete, sponsors collect data, manually enter it into multiple systems,
analyze it, and package it at the end of the phase one trial, again at the end of the phase
two trial, and again at the end of the phase three trial. It's tedious. What's more is the dead time
has been expanding. It was 25 percent of the drug timeline. Then it turned to 35 percent and now
we're at 45 percent. So we are literally seeing an increase in the amount of time spent on paperwork
even as the amount of time spent in the clinical trials is decreasing. That's not a good trend,
especially given the fierce global competition that we have as a country. We have to retain
our position as the world leader in biotech and cures. Today the FDA is announcing a bold new
approach that could fundamentally transform the clinical trial landscape. In partnership with a
major drug developer, a tech company, MD Anderson and the University of Pennsylvania, we are
announcing the first ever real-time clinical trial. This is not a theoretical, this is not a
plan, this is not a statement of an intent, this is not a framework or a panel discussion about
doing it. Today, up and running, is a real-time clinical trial live today. What exactly is a
real-time clinical trial? Well, it's when FDA reviewers can see safety signals and clinical
endpoints in the cloud in real time as a clinical trial is happening. It's revolutionary. So when a
patient in a clinical trial develops a fever or is hospitalized or a tumor shrinks and a radiologist
reads the new tumor size, the FDA regulators can see in the cloud in real time exactly what's
happening with the pre-agreed upon endpoints and safety signals. In addition to the promise of
delivering more medications faster, today's action is an important step towards a broader goal
of seeing more continuous trials. We have to do this in an iterative stepwise fashion
but this is a milestone day. It's also an important step in pandemic preparedness.
Imagine a circulating pathogen with a 50 percent mortality rate, case fatality rate, that is so
high it shakes the country. Wouldn't you want to see a real-time clinical trial to get that
information in real time? Or imagine you're a child who's deaf or has a debilitating cancer
with a potentially promising therapeutic on the horizon. You would want a real-time clinical trial.
The reason we haven't done it so far is that the technology was not there, the will was not there,
and we just didn't have the right time and space to make it happen. But thanks to the many of the
people behind me and the leadership of Jeremy Walsh and the power of cloud computing and the mass
authority of electronic health records that can now be accessed at scale,
with of course the patient's consent, we can now do things that were previously impossible.
We showed this dashboard of clinical endpoints and safety signals to some of our FDA reviewers
and they said that they have all kinds of ideas of what else can be added, other data points,
and other future promise and potential for this type of technology. It's a great way to interact
with the actual trial on a data-driven basis, in the words of one of the reviewers.
This is also a critical step towards a broader goal that we have of seeing no lag time between
the phases of clinical trials. Using better technology and common sense, we can deliver
more cures and meaningful treatments to the American public without cutting any corners
on safety, and that is always our number one goal, is safeguarding the public.
We can use common sense and better technology. I personally have been traumatized by PowerPoint
in my lifetime, so I'm not going to show a PowerPoint to you except to show you one
graphic, which is the drug development and approval process. This is how a drug goes
through the process. Now every part of this process is being re-engineered to ask ourselves
what workflow can we make more efficient without cutting any corners on safety. Beginning with the
pre-IND process, we are trying some new things. We are reducing animal testing. No longer do you
need two species of animal testing routinely. This is a big endeavor led by the folks at CDER
and Tracy Beth Hoag. Thank you for that work, Tracy. We are looking to reduce and defer
requirements for the IND application. Some of those requirements can be received later
and only in summary form so that we are only focusing on safety in the Phase I trial in that
requirement. We are looking to reform the IRB process. We are announcing today the first ever
FDA real-time clinical trial in partnership with some of the representatives here with me on stage.
We are moving from two-to-one pivotal trials as a baseline default with exceptions, allowing
Bayesian statistics that enable us to say, hey, you can stop a clinical trial for either
overwhelming efficacy and safety or a safety signal that may require halting a trial.
And the filing period is two months. That is done in two minutes with our new AI tool that
shaves two months off the decision of every drug that comes through the FDA. It will very soon.
It may not sound like a lot, but if you're somebody who was waiting for Zongortenib,
the new treatment for HER2 mutated non-small cell lung cancer, and you're in hospice and that drug
can get you out of hospice, those 60 days have a big meaning. We have our new national priority
review program. We have now seven decisions out, I believe, and 21 products were announced with the
three psychedelics announced last week. And finally, in the post-marketing period, we are
using big data and harnessing the power of mass electronic health record access and cloud
computing to be able to have eyes on a drug so we can see the safety and efficacy immediately
after the FDA decision is made to approve. So with that, I would like to thank the many
scientists from the FDA, some of whom are represented here, who have worked hard on
each of these steps. This initiative today represents FDA common sense modernization in
our campaign to see more cures and meaningful treatments for everyday Americans. I want to
quickly thank those who are joining today, Dr. Emma Marr, Professor of Medicine and Pharmacology
at the University of Pennsylvania and Senior Vice Dean for Clinical Research and Translational
Research. Dr. Amy McGee, Senior Vice President at AstraZeneca. Kent Tolk, CEO of Paradigm Health,
a valuable partner in this endeavor. Dr. Jennifer Keaton-Lytton, Chief Clinical Research Officer
at MD Anderson Cancer Center. Dr. Paul Burton, Chief Medical Officer and SVP at Amgen. And Dr.
Melina Munkur, FDA's own Acting Chief Medical and Scientific Officer. Thank you, everybody,
for joining. And now I'll turn it over to the man who helped coordinate this entire effort,
Dr. Jeremy Walsh. Jeremy, why don't you come over here, our Chief AI Officer at FDA.
Thank you, Marty. Thank you, Commissioner. And thank you for everyone for being here with us
today. This one for me started around like eight years ago when I came in one day to, you know,
I was a contractor for the FDA and I came in to talk to a gentleman by the name of Dr. Sean Kozin
about just some ideas for doing some innovative things. During that meeting, we came up with,
you know, a clinical trial, which we actually ended up executing. It was an interesting one.
It's around AI and pain. But one of the things that Sean did was he sort of walked me through
a clinical trial. I had no idea. I was like, well, it sounds interesting. This should be easy,
right? You know, doing a clinical trial. And so he talked to me about sort of the first clinical
trial, right? It was actually for scurvy, right? It was on ships and they basically
tried to figure out what could cure scurvy. And so he walked me through that and then
talked to me about sort of the, you know, where the current sort of state of the art was,
where that people were packaging data, you know, and collecting this data and then submitting all
this data to the FDA. And I said, well, that's, that sounds like, well, I understand that's what
people have done is what about today, right? Where are they today? And he's like, well,
that's still where they're at today. What they were doing basically in the 1960s is kind of,
for the most part, what they're doing today, just a slightly different. So I remember going back
and writing a sort of, I guess, like a white paper to talk about, you know, should the FDA
implement real-time clinical trials? And I sent that up and talked to some people and they were
like, yeah, there's no one really in charge of that here. Like we want, we think about it. There's
been thoughts about it, but there's no one really sort of in charge. And so I kind of shelved that.
And then time went on and finally the opportunity presented itself to come back in here.
This was something that we started as a team in, or I'd say around June of last year,
May or June of last year, this was a focus area. As the commissioner mentioned, we, you know,
when he put up the graphic, we understand each part of those, the phases of the process and
where sort of the weight that that sort of, as the commissioner mentioned, dead time sits.
And so we initially sort of were like, we're going to see, can we solve this part of the problem?
What can we do to move the clinical trial part as fast as possible? It's interesting because the
FDA doesn't really run clinical trials. Those go run outside of the FDA, right? We do our reviews
and we look at a lot of information, but we don't do the actual trial, but what could the FDA do
as a partner in accelerating this? So we began those conversations last year,
started them with AstraZeneca and Amgen. I believe the first meetings when we said what we wanted to
do was took a couple minutes for people to be like, well, you want to not see all the data,
right? You only want to, you just want to see certain pieces or the signals of the data.
After a series of meetings, we were able to sort of get past that. And then things got really kind
of moving, I think, in terms of the end of sort of last year. And we were able to find the right
technology partner in Paradigm Health over there. And this whole process was turned on and live
this month. And so, and what is this? What is a real-time clinical trial for the FDA?
Well, a real-time clinical trial for the FDA is we're looking for signals.
You know, as the commissioner mentioned, we already get tons of data, right? We've been
getting tons of data for, you know, decades. What we're interested in is,
is can we make a decision off of less information? Can we make a decision off of signals information,
right? And so what we're starting is we're starting with, we work with the sponsor,
we define the criteria for what needs to be reported. They take that information,
they work with a technology partner, they then provide us signals, right? And so this is the
start. This is not probably where we end up, but this is the start. We have those signals coming
in live. We see them. We understand what's happening on the trial. And I think this is
kind of a transformative thing where what the FDA is looking for and what we're trying to do is
whereas we're re-imagining, you know, what information we need and when we need it in
order to make a decision. We get information overload sometimes. We don't need everything
that we receive. So this is a process for us and this is a process that will continue.
But I really want to just send my thank yous off to really everyone that was involved in this,
both from our industry partners that made this possible, our technology partners, and finally,
the most important people are the sort of the FDA staff that worked to make this a reality.
This worked across for different review divisions. This worked across different partners,
across different center directors in order to sort of take this concept and make it real.
And so it's a huge shout out and a huge thank you for everyone. And with that,
I will be passing it off to Dr. Jennifer Linton, who can sort of talk about this from a, you know,
from a perspective of sort of the organizations where these are run, right? You know, MD Anderson,
one of the best, you know, cancer sites in the country. You know, they do a ton of amazing work
to help patients. And so really to understand from their perspective, what does this mean,
right? What would real-time clinical trials mean, you know? And I think we'll also hear
that from the sponsors as well as also from the technology vendors. So with that, thank you,
Jennifer. Thank you. So cancer can come into anyone's life at any time. And when you need
the hope of a new treatment, you want that new treatment right away. At the University
of Texas MD Anderson Cancer Center, we pride ourselves on having more patients participate
on cancer treatment trials than anywhere. And we are all united in a single focus to end cancer.
So thank you, Dr. McCary, to Dr. Walsh and our friends at the FDA who are proactively working
to get cures faster to patients. And we're here to partner with you. So the good news is,
is that more people are being cured and living with cancer, but we still have many who need
new treatments. And we're having an explosion of new scientific discoveries. And these breakthroughs
have a real promise. So our current challenge is to take these breakthroughs and translate them
through scientific, rigorously scientific clinical trials. And these clinical trials are often our
patients' best hope, especially for our patients with advanced cancers. Now, at the same time,
we're having a huge surge of new technologies and capabilities that are going to allow us to
accelerate these breakthroughs. So right now, we collect vast amounts of complex data, often
manually, and then we put them in multiple different systems that were never made to
talk to each other. So when we do that, we take the time away from our patients and our researchers,
we increase cost, and we slow down the time it takes to get the answers we need for our patients.
So we have a real opportunity here to streamline the process of collecting the data
so that we can effectively evaluate a new treatment. So if we speed this up,
we can see earlier signals, whether that's efficacy or real-time toxicity monitoring.
So right now is the time to harness these tools to make these clinical trials more accessible
to patients. Now, it could be that we're activating trials so much quicker, we have more options,
whether it's using new tools to get trials to patients closer to where they live, or as we're
talking about today, using new and innovative ways to collect, curate, and analyze the data.
Lastly, research, breakthroughs, discoveries, they're happening at an unprecedented pace.
And it's time that we bring our approach to clinical trials up to speed. I can say,
as an oncologist, as the daughter of two parents with cancer, and as someone diagnosed with cancer
this year, I just finished surgery and radiation, and you never know when it's going to be you,
or whether it's going to be one of your loved ones. If you need the hope for a clinical trial,
you want that right then. So on behalf of myself and my colleagues at the University of Texas MD
Anderson Cancer Center, we're proud to work together to pilot, test, and advance anything
that's going to accelerate cures for patients. So with that, I'd like to invite Dr. Paul Burton,
he's the Senior Vice President at Amgen. Thank you. Good afternoon, everybody. Commissioner
McKerry, Dr. Walsh, I want to begin by thanking you both and all of your colleagues here at the
FDA for your continued leadership and your openness to new approaches that can advance
patient care while upholding the highest standards of safety and scientific integrity. At Amgen,
everything that we do starts with patients, just as it does with all of you. We believe that
innovation should not only deliver breakthrough medicines, but also rethink how we develop them.
That means supporting approaches that bring research closer to patients where they are,
and helps reduce the barriers to participation. And this is where the promise of more integrated,
data-driven approaches comes into focus. By leveraging data from electronic health records,
we have an opportunity to help democratize clinical research. We can reach broader
patient populations and generate insights in ways that are more reflective of everyday
clinical practice. And this is a meaningful step towards greater health equity and innovation.
But I do want to be very clear that pragmatic clinical research, pragmatic clinical trials,
does not mean conducting clinical research with less rigor. The fundamentals of good science
do not change. Protocol development, protocol oversight, informed consent,
monitoring, strong governance, FDA review, all of that remains absolutely standard and
absolutely essential. Patient safety and data integrity will always be our North Star.
The new approach is designed to sit alongside traditional approaches to doing clinical
research and randomized studies, and contribute to a broader development program and a broader
evidence base. The pilot program that we are doing with Tarlatamab, our small cell lung cancer
medicine, really exemplifies this. Each of the methods, whether it's a pragmatic real-time
clinical trial or a standard clinical trial, can sit together and can help build that complete
and comprehensive evidence base. It's an important opportunity for us all to learn now and understand
whether an embedded electronic health record native system and model can work credibly,
responsibly, and at scale. And we believe it can. If successful, it could help us move more
efficiently in the future without compromising rigor of clinical science or patient safety.
Because, as you just heard, those patients absolutely depend on this every day.
By working together, we can help modernize how evidence is generated and ensure that
progress reaches more people more efficiently. In the end, for all of us, our goal and our aim
is to accelerate cures. So thank you again to the FDA and to our partners at Paradigm Health
and to everyone who contributed to this important effort. Most importantly, thank you to the patients
who inspire and guide all of the work that I think all of us at this meeting do. And I now
have the pleasure to introduce Professor Emma Marr. Professor Marr is Senior Vice Dean of Clinical
and Translational Research at University of Pennsylvania Health System. Dr. Marr.
Good afternoon, everybody. It's an absolute pleasure to be here with you today. Commissioner,
you and your team, thank you for convening us. And to my colleagues, what an opportunity
to work in true partnership. I've been at the University of Pennsylvania for 32 years.
Throughout that time, I have been a trialist working on the front lines, recruiting patients
while also taking care of them in their health care journeys. My first path down the way of
developing a drug was in 2010. It was for a rare genetic disorder. It took me exactly 13 years
to get that through FDA approval. It happened on Christmas Eve. It was the best Christmas ever.
Now, 32 years later, or 22 years later, 15 years later, the one thing I can say
is that as a community, we are wonderful scientists and we are wonderful innovators.
However, now is the time to innovate in our process. It's something that has been sorely
lacking. I welcome this approach by the FDA to bring novel tools such as AI, data transformation,
data transit to bear on our process because we are at an absolute pivotal stage in the drug
development industry. We are losing this work outside of the U.S. We need to keep it in the U.S.
We need to keep our workforce trained. We need to keep them engaged. We need to consider the
barriers to reduce the way in which we do this to bring it to practice much sooner.
This particular innovation that involves one of our investigators at Penn, Elise Chan,
is going to revolutionize not necessarily the work for the FDA, although that will help,
but what it will actually do is help our research coordinators, our nurses, our project managers.
They're so hard to find, and when you find them, they're virtually impossible to keep.
So by easing this process at the academic interface of patient care, we'll have an
absolutely revolutionary approach in our ability to sustain this workforce and to keep this type
of work occurring within the U.S., most importantly. So I thank the FDA for giving us this
opportunity to be here today. I also thank the audience for being interested in the topic.
This needs to be sustained. This is a wonderful idea today. It takes persistence and resilience
to make sure that wonderful ideas are implemented and adhered to throughout the future.
So thank you for this opportunity, and again, I would also like to thank every single patient
who has donated their time to participate in the development of novel therapeutics.
Oh, I have an introduction, and it's my honor to introduce Amy McKee, who is the Senior Vice
President of Oncology, Regulatory Science, and Strategy at AstraZeneca.
Thank you, Commissioner McKerry, Jeremy, members of the FDA, and all of you here today,
including our partners who are participating in this proof of concept.
All of you, thank you. This program is an important first step towards strengthening
clinical trial data collection. It underscores the importance of strong collaboration across
the entire healthcare ecosystem and plays a critical role in advancing innovative science.
The ultimate goal is to move data as quickly as possible across this ecosystem to accelerate
our ability to bring new therapies to patients to make a meaningful difference in their lives.
Today, AstraZeneca has more than 100 phase 3 trials underway, most of which are being performed
here in the U.S. as well as across the world, and we have 20 potential new medicines in our late
stage portfolio. These efforts, similar to my peers here today, are studying some of the most
transformative medicines and some of the most difficult to treat diseases. In oncology, for
example, we have a bold ambition to eliminate cancer as a cause of death and a focus in key
tumor areas such as lung, breast, liver, and blood cancers, just to name a few. In addition,
we are developing a broad portfolio of personalized treatments that target different
subtypes across all stages of cancer. Today, the pace of innovation and new advances in science
and technology is truly remarkable. We commend the FDA for recognizing this as an opportune moment
to pursue new regulatory approaches that will further meet this rapid pace of innovation.
Furthermore, this is a first step in FDA's ambitious vision to move toward a future
where clinical trial updates are shared in real time. At AstraZeneca, we strive to transform
the future of health care by unlocking the power of what science can do for people, for society,
and for the planet. At the heart of this, what drives each and every one of us here in this room
today, day in and day out, are the patients we serve. We appreciate the opportunity to be a part
of this proof of concept as all of us continue to advance on bringing safe, effective medicines
to the patients in the United States and around the world. Thank you again, Commissioner McCary,
Jeremy, and all of you for joining us today. I would like to introduce now founder and CEO
of Paradigm Health, Kent Tolke, who is one of our partners in this. First of all, I want to thank
the Commissioner and Jeremy and really the entire FDA team for what has been a phenomenally fast
journey the last six months. I have been in this industry for 35 years. I have seen thousands of
cancer patients die in that time. The reason speed is critical, the reason this initiative
is critical, is because every day an efficacious drug stays off the market, costs patient lives.
Every day a patient can't get access to a life-saving medication that's part of a clinical
trial, costs lives. The folks on this stage behind me, everybody at the FDA, the team we have at
Paradigm Health, moved at a speed I have never seen in my career to get us to this point, to have an
active, live, real-time clinical trial. That impact is not theoretical. It is felt by family members
and patients in real time today. They sent the tech guy up here to talk about patients, which
is a little bit different, but I spent most of my career on the patient side until I saw the
challenges that we were facing. Too few trials were getting to too few patients, and I launched
a tech company. But what brings us here today, everybody on this stage, is a shared mission
to make sure that all patients across this country have a real opportunity to participate
in clinical trials and benefit from innovative therapies. Not just patients who happen to live
in a big city or near an academic medical center, but the patients that receive their care in the
community and in rural healthcare settings as well. Because today, where you live and where you get
your healthcare still plays too big a role in deciding whether or not you'll even have access
to those drugs or those clinical trials. With the launch of this FDA study, Paradigm Health's
platform, along with our pharma and industry partners and healthcare system partners we have
on stage here today, we've laid the foundation to better serve all Americans with a higher quality
accelerated model. This brings together all of the skill sets of leading academic medical centers
like MD Anderson and the University of Pennsylvania, who are at the forefront of complex
and high quality research. Their role is essential. They anchor the rigor and the scientific method
and the quality behind the work that we've launched here today. At the same time, this model expands
into the community and into the rural setting, a system that can be scaled today because of
technology. Through this collaboration, technology is now helping to reduce the extremely complex
workflow that is required of study coordinators and physicians at these healthcare systems to
participate in research. That means more patients can actually participate and choose clinical trial
options at home where they receive their care with physicians and caregivers that they trust and know.
That's an important shift because what it does is it makes clinical trials not an exception,
but it can become the rule. It also makes sure that clinical trials can be part of everyday care.
Another part of this effort that we're launching is speed. The ability to get trials done quicker
in a more broad representative population and broad care setting gives us an opportunity to
understand in real time and quicker how drugs are actually working in the community. That can help
the FDA and sponsor companies make more informed decisions along the way in real time instead
of waiting until the end. Ultimately, this shortens the pathway from promising science to treatments
that actually treat patients. When this model becomes the standard, a patient in small town
America should have the same opportunity to participate in a clinical trial and get a
life-saving medication as someone treated in a major academic medical center. That's the standard
we should be working for. That's the care all patients deserve today, and it's why partners
like the folks on this stage matter. Together, the FDA, AstraZeneca, Amgen, MD Anderson, and the
University of Pennsylvania, and the entire team at Paradigm Health, we're working to demonstrate
what a modern, transparent, and more inclusive clinical trial system can look like at a national
level. One that expands access, one that moves faster, one that helps bring new treatments and
hopefully cures to all Americans regardless of where they live or get their health care.
We're extremely proud to support the FDA in this effort and grateful to be part of something that I
think in my career can finally make a difference for patients. With that, I'd like to introduce
the FDA Deputy Chief Medical Officer, Malika Mundkar. Hi everyone. I want to start by thanking
the Commissioner and Jeremy and everyone else on the stage for incredible work. Particularly
Commissioner and Jeremy, I want to say that this is yet another really bold idea, and I think over
the past year we have seen things happen at FDA that we didn't think were possible. Some of us
didn't think were possible, and we've seen it happening. So I think I want to encourage people
to think of this idea the same way. It sounds like a big vision, and it is, and it's already
happening. It's happened, and the goal is to expand it. So in the next phase of this initiative,
the idea is to scale this across the agency. We have already engaged with internal subject matter
experts, and as of today, we've issued an RFI to solicit feedback from the public about how we can
scale this in a way that adds the greatest value for public health. So I encourage you guys to
check that out on the Federal Register and share your ideas, or you can email us, you know,
any form of communication is welcome as we kind of shape this together going forward. Thank you.
All right, thank you again to all of our amazing speakers. We're now going to start our Q&A portion.
I ask that you keep it to the topic of today's announcement and when you're handed the microphone
to also state your name and outlet. So, Arthur, we can start with you.
Arthur Jones II, ABC News. Commissioner McCary, I hope you're doing okay after the White House
Correspondent's Dinner over the weekend, but given today's announcement, do you have any
outstanding concerns about missing safety signals or not having enough time to review the data from
clinical trials? Thank you. Arthur, good to see you and thank you for mentioning that about
Saturday. It was quite an experience. I was sitting in the front and it just makes you realize
that none of us are going to be here forever and that life can be short. These are thoughts I've
had as a cancer doctor at the bedside, but I just, you know, want to take a moment and thank the
security team that was able to stop the perpetrator. On the safety signal, safety is our
number one priority. It's a great question you're asking. The companies, that is the sponsors and
the FDA scientists, agree on safety signals and clinical endpoints with any ongoing study design.
So, that agreement is still part of this process. We're going to preserve that and because those
safety signals can be sent directly to the FDA, they will be safety signals that are mutually
agreed upon. It'll do, that'll achieve a couple things. One, it'll limit our purview to what's
important for the approval process. And number two, it'll allow us to pilot a new concept because
initially we will take both the data submitted the routine way and the data that we're able to
see in real time and we'll do both and that's part of the pilot process. And then by definition
of a pilot, we'll reassess at the end of the pilot to see what we can do better and we want to learn.
That's why we have an RFI going out today. That's why we're taking questions. That's why we're
socializing the idea. Dr. Jimmy Walsh has been working on this. I keep calling him Dr. Walsh,
but he's been working on this since the day he arrived and I think this has been an idea that's
been growing. It's come up in conferences prior to my time at the FDA, but Jeremy got it done.
Thank you, Commissioner. Yeah, I think that the primary objective of the agency is safety,
you know, safety and efficacy and so none of those things change. I think the Commissioner mentioned
is that as part of even the prototype that we did, we're going to get the same data. We're
going to get the data through the normal regulatory process that we have established today as we also
see it in real time. So that was the prototype to sort of see this data flowing in, right?
The goal here is to sort of get to a regulatory decision in a faster timeline, right, without
compromising any safety. We actually believe that you can probably do more analysis. You can look
at other things. Industry will invent and come up with new ways they can pull different pieces of
data together. So you'll actually, the goal here is to kind of raise the bar about what can be done,
but this isn't a, there's no sacrifices being made here in terms of both the prototype or the pilot.
Okay, no more questions. I'm shocked. Yeah. Hi, Lauren Gardner from Politico. This is for
Commissioner McCary. You mentioned earlier, you know, kind of all the different aspects of the
clinical trial process and then review process that you're looking to, you know, kind of
revolutionize here in the different centers. You pointed to Dr. Hogue's efforts on animal studies.
Can you give us an update on some of these leadership positions that'll be critical to
carrying this work forward in the, you know, near and medium term? Drug center, biologic center?
Thanks for the question. So the search for the director of the biologic center is going
extremely well. We have terrific candidates that, so that process is going well. No decision
has been reached at this point, but I expect it in the coming weeks. On the broader FDA approval
process, we want to keep iterating, getting ideas, re-engineering that process. So we're going to,
we're going to keep doing that. The animal testing part that you mentioned is a key part of it.
Did I answer your question? Okay, good. Yeah, he's right here. Hi there. This is Maisha with
Pink Sheet. So I, my question is for Commissioner McCary. Would FDA's proposed optional clinical
trial pathway would hinge on deeper reforms to the IRB process? And how is FDA planning
to make IRB reforms, if you could elaborate a bit on that? Sure. And anyone else who would like to
chime in, feel free. But here's what I'd like to say. Good to see you, Maisha. So
the IRB process in the United States is an unfortunate rate limiting step to the entire
U.S. healthcare research infrastructure. A committee of hospital volunteers that sometimes
meets monthly is literally a rate limiting step. And so we have to rethink how we do
IRB approvals. We have to ask big questions like, can more institutions use central IRBs,
or if they don't use the central IRBs and recognize them, turn their own IRBs around
in 30 or 45 days. We have to ask those big questions. As you know, more clinical trials
are starting in China than in the United States. This is something that happened in the preceding
four years before I came to office. And that has been literally an exodus of phase one trials.
Some are also going to Australia. We have to think about how we can do things competitively,
efficiently, and yet not cut any corners on safety. And so that means reexamining the entire
IND process, the requirements that we have, what can be deferred until later in the process. Do you
need six months of stability testing to do a first in human injections? Do you need
the detailed raw data before you initiate the IND? Or can summary data suffice until the send file can
be delivered later? We have to reexamine that entire process. So we are working with universities
and conversations to solicit their ideas on how to reform the IRB approval. We are looking at
our own requirements and have teams actively, many of whom are here, the scientists at the FDA,
are actively working on streamlining those IND requirements. And I expect a
series of announcements in the coming one to two months where we will lay out very clearly a new
path for phase one clinical trials and INDs in the United States so we can retain our leadership
position. Thanks. All right, we'll take one more. Hey, Frank Conco from GovExec. I feel like this
is the latest in a series of big, bold technology moves that FDA has been doing over the past year.
You're doing it without really much more resources or funding. I'm curious, Commissioner, if you could
just talk about the transformation that's been afoot over the last year and change and maybe what
else we could expect in the coming months. Maybe Dr. Mooncourt can answer. I will just preface by
saying that thanks to the modernization efforts by our entire IT and AI team here at FDA,
we have been able to get away from the fiefdom culture where every center has had their own
license agreement for the same software and their own system for, say, adverse event reporting,
application uploading, safety monitoring systems, and we have done a massive consolidation. So we
now have one system instead of 40 systems that intake applications. We take applications for
cat food and vaccines for farm animals and devices and wearables and tobacco and cosmetics.
We had 40 different systems. Now we're going to one. We had three major data monitoring systems
for safety that we tapped. We're going to go to one. And we had seven adverse event reporting
systems, all built separately, all clunky, all frustrating. We did our own internal analysis,
and 60% of the people that went to our own adverse event reporting systems to report an adverse
event gave up after they started. They never got through it. The final report was never filed.
We can see that they went on there. So we don't want systems where you go in to do a simple task
and you're in the middle of it and you think, I'd rather die than do this. So we are going to one
adverse event reporting system instead of CARES and FAERS and MERS and MAUD. So all of that is
going to save us at least $120 million a year. What are we doing with that $120 million?
We are reinvesting it in our scientific community. We are hiring almost 3,000 new scientists.
We are investing in new technologies. And that added reserve in our resources will support the
bold reform agenda that we have. Dr. Mooncore? So I think it's a really good question. You know,
how are we going to manage this resource-wise, right? But I do want to stress the fact that
FDA is, and the people at FDA having worked here for many years, are extremely mission-oriented,
right? We are serving the public. We're serving patients. And that is our North Star, right? So
for people to, you know, spend time on something that they're passionate about, I would say there's
some fuel in there that drives motivation. But I think the success of any of these bold initiatives
really comes from leadership by the staff, you know, the frontline staff, the leaders that really
have the longstanding expertise. And that's, I think, driven the success of other initiatives
and will be a critical part of this one as well, which is really engaging with our internal subject
matter experts to help lead these and design these in a way that's operationally feasible
and really effective. Okay. Thank you so much for coming today. And that's a wrap. Thanks.
